Everything below concerns dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-23. Numbers and descriptions here follow the published literature rather than marketing material.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
== Capabilities == OpenELIS covers the laboratory testing workflow, including patient and sample management, results entry and validation, quality control, and reporting, and consolidates clinical, environmental, and vector-surveillance testing on a single platform, an approach the project describes as "One Health". Quality-control features include reference-range enforcement, Westgard-rule monitoring with Levey–Jennings charts, and corrective-action tracking used to support ISO 15189 and SLIPTA accreditation.
=== Prout's hypothesis and the whole number rule === The whole number rule states that the masses of the isotopes are integer multiples of the mass of the hydrogen atom. The rule is a modified version of Prout's hypothesis proposed in 1815, to the effect that atomic weights are multiples of the weight of the hydrogen atom.
Achene – most commonly seen in aggregate fruits (e.g., strawberry, see below) Capsule – (Brazil nut: botanically, it is not a nut) Caryopsis – (cereal grains, including wheat, rice, oats, barley) Cypsela – an achene-like fruit derived from the individual florets in a capitulum: (dandelion) Fibrous drupe – (coconut, walnut: botanically, neither is a true nut.) Follicle – follicles are formed from a single carpel, and opens by one suture: (milkweed); commonly seen in aggregate fruits: (magnolia, peony) Legume – (bean, pea, peanut: botanically, the peanut is the seed of a legume, not a nut) Loment – a type of indehiscent legume: (sweet vetch or wild potato) Nut – (beechnut, hazelnut, acorn (of the oak): botanically, these are true nuts) Samara – (ash, elm, maple key) Schizocarp, see below – (carrot seed) Silique – (radish seed) Silicle – (shepherd's purse) Utricle – (beet, Rumex) Fruits in which part or all of the pericarp (fruit wall) is fleshy at maturity are termed fleshy simple fruits. Types of fleshy simple fruits, (with examples) include:
==== Moisture movement directions for diffusion ==== It is reported that the ratio of the longitudinal to the transverse (radial and tangential) diffusion rates for wood ranges from about 100 at a moisture content of 5%, to 2–4 at a moisture content of 25%. Radial diffusion is somewhat faster than tangential diffusion. Although longitudinal diffusion is most rapid, it is of practical importance only when short pieces are dried. Generally the timber boards are much longer than in width or thickness. For example, a typical size of a green board used for this research was 6 m long, 250 mm in width and 43 mm in thickness. If the boards are quartersawn, then the width will be in the radial direction whereas the thickness will be in tangential direction, and vice versa for plain-sawn boards. Most of the moisture is removed from wood by lateral movement during drying.
Sources: en.wikipedia.org
Lateral flow assays have played a critical role in COVID-19 testing as they have the benefit of delivering a result in 15–30 minutes. The systematic evaluation of lateral flow assays during the COVID-19 pandemic was initiated at Oxford University as part of a UK collaboration with Public Health England. A study that started in June 2020 in the United Kingdom, FALCON-C19, confirmed the sensitivity of some lateral flow devices (LFDs) in this setting. Four out of 64 LFDs tested had desirable performance characteristics according to these early tests; the Innova SARS-CoV-2 Antigen Rapid Qualitative Test performed moderately in viral antigen detection/sensitivity with excellent specificity, although kit failure rates and the impact of training were potential issues. The Innova test's specificity is more widely publicised, but sensitivity in phase 4 trials was 50.1%. This describes a device for which one out of every two patients infected with COVID-19 and tested in real-world conditions would receive a false-negative result. After closure of schools in January 2021, biweekly LFTs were introduced in England for teachers, pupils, and households of pupils when schools re-opened on March 8, 2021 for asymptomatic testing. Biweekly LFT were made universally available to everyone in England on April 9, 2021. LFTs have been used for mass testing for COVID-19 globally and complement other public health measures for COVID-19. Some scientists outside government expressed serious misgivings in late 2020 about the use of Innova LFDs for screening for Covid.
A unique identifier assigned by the investigator to each trial subject to protect the subject's identity and used in lieu of the subject's name when the investigator reports adverse events and/or other trial-related data. (ICH E6) Subject/Trial Subject
==== Sweetened soybean ==== Sweet-boiled beans are popular in Japan and Korea, and the sweet-boiled soybeans are called "Daizu no Nimame" in Japan and Kongjorim (Korean: 콩조림) in Korea. Sweet-boiled beans are even used in sweetened buns, especially in Mame Pan. The boiled and pasted edamame, called Zunda, is used as one of the Sweet bean pastes in Japanese confections.
Sources: en.wikipedia.org
=== 2020s === During the COVID-19 pandemic, the company was one of the major developers and processors of COVID-19 testing. In March 2020, Labcorp received emergency use authorization from the FDA for a test for SARS-CoV-2. In April 2020, the company developed the first COVID-19 test in which people were able to collect a sample at home. In July 2020, the company was processing 165,000 COVID-19 tests per day. In December 2021, the company acquired Toxikon, a contract research organization developing non-clinical testing services. In February 2022, the company acquired Personal Genome Diagnostics and its liquid biopsy and tissue-based genomic product, for $450 million in cash plus a possible earn-out of an additional $125 million. Also in February 2022, Labcorp entered into agreements with Ascension, one of the nation’s largest Catholic and nonprofit health systems, to manage Ascension's hospital-based laboratories in ten states and purchase assets of the health system's outreach laboratory business. In June 2023, Labcorp completed the corporate spin-off of Fortrea. In August 2024, Labcorp acquired the assets of bankrupt Invitae for $234 million. In December 2025, Labcorp acquired the ambulatory lab businesses from Community Health Services (CHS) in 13 states for $194 million. In January 2026, it was announced that Labcorp had sold select assets of its early development medical device testing business to NAMSA, a medical device testing, clinical research, and regulatory consulting company.
== Contraindications == Etifoxine is contraindicated in people with circulatory shock, severe liver impairment, severe kidney impairment, myasthenia gravis, galactosemia (due to lactose in the drug formulation), severe respiratory failure, and hypersensitivity (allergy) to etifoxine. The medication is not recommended in children or adolescents under the age of 18 and is not recommended during pregnancy and breastfeeding due to insufficient data. Caution is warranted with regard to combining etifoxine and other central depressants such as benzodiazepines, central analgesics, antipsychotics, sedative antihistamines, and alcohol.
dadantii possesses the ability to spread to new regions of the host and other areas may begin to display symptoms. Colonization within the xylem restricts flow of water causing loss of turgor pressure and wilting of foliage and stems. Restricted movement of important plant compounds eventually lead to death of the host.
=== HIV in transgender people === Transgender people are infected by HIV at disproportionately high rates worldwide. According to the U.S. Centers for Disease Control and Prevention (CDC), in the United States in 2019, 2% of patients newly diagnosed with HIV were transgender, a higher percentage than the 0.3% of the U.S. population which self-identified as transgender. HIV prevalence is higher in transgender women compared to transgender men. One systematic review and meta-analysis found that overall HIV prevalence around the world was 19.9% in transfeminine individuals and 2.56% in transmasculine individuals. Transgender sex work are at further enhanced HIV risk, and transgender populations in African and Latin American regions have higher HIV prevalence. Following CDC and USPSTF guidelines, UCSF recommends HIV screening for all transgender people at least once. Screening may be repeated on a case-by-case basis, depending on the person's risk for contracting HIV. The risk should be assessed based on the individual's sexual behavior. HIV risk assessment screening should account for the individual's specific anatomy and what type of sexual acts and behaviors the individual partakes in. For instance, HIV prevalence in transgender women is notably high, and a risk factor is that transgender women are frequently noted to partake in receptive anal sex with biologically male partners. There has been a tendency for these individuals to be grouped with "MSM" in research on HIV risk factors, due to a supposed shared mechanism of biological vulnerability to HIV transmission.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.